Posted inWire
Gilead Sciences to acquire Immunomedics in a $21 billion deal
The agreement will provide Gilead with TrodelvyTM (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by FDA in April. SACRAMENTO: Gilead Sciences Inc. and…
